Tradestie Institutional Equity Comparison Engine

BGLC vs CLBR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BGLC Overall Edge

BGLC Captures Institutional Edge (1โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioNexus Gene Lab Corp Common stock (BGLC) driven by superior Growth & Margin while CLBR counters with relative strength in Momentum & Technical. Fundamentally, BGLC trades at N/M Forward P/E with -88.2% operating margin (-96.6% YoY revenue) versus CLBR at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, BGLC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLBR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BGLC N/M vs CLBR N/M Fwd P/E
Growth & Margin Winner BGLC
Op Margin -88.2% vs N/A ยท YoY -96.6% vs N/A
Momentum & Technical Winner CLBR
1Y -85.0% vs -0.5% ยท 52W Pos 1% vs 5%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BGLC NASDAQ
BioNexus Gene Lab Corp Common stock
Services-Medical Laboratories
$0.68
+0.0% 1D
Market Cap $2.0M
1M Return -42.86%
1Y Return -84.99%
Forward P/E N/M
Unified AI Score
44.2 / 100 HOLD
Tech 45.0 Fund 42.0 Flow 50.0 Mom 63.9
CLBR US Equity
CLBR
Institutional Equity
$10.02
-0.1% 1D
Market Cap N/A
1M Return -0.4%
1Y Return -0.5%
Forward P/E N/M
Unified AI Score
47.5 / 100 HOLD
Tech 50.0 Fund 54.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BGLC -84.99% CLBR -0.5% Spread: +70.54 pp (CLBR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BGLC TTM Op. Margin: -88.2% CLBR TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGLC vs CLBR. Trailing 12-month operating profitability (BGLC -88.2% vs CLBR N/A) and valuation multiples (BGLC N/M vs CLBR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BGLC (5) vs CLBR (3)
Institutional Metric BGLC CLBR Criterion Row Winner
Market Capitalization Scale $2.0M N/A Larger Scale BGLC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -96.6% N/A Higher Growth BGLC
Operating Margin (TTM) Profitability -88.2% N/A Higher Margin BGLC
Net Profit Margin Profitability -82.4% N/A Higher Margin BGLC
Return on Equity (ROE) Capital Efficiency -33.7% N/A Higher ROE BGLC
52-Week Range Position Momentum 1% ($1โ€“$5) 5% ($10โ€“$10) Stronger Trend CLBR
Beta / 30D Volatility Risk Regime 1.34ฮฒ ยท 86% Vol 0.08ฮฒ ยท 4% Vol Lower Realized Risk CLBR
Unified Institutional Score Composite Signal 44.2 / 100 (HOLD) 47.5 / 100 (HOLD) Higher Composite CLBR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BGLC vs CLBR Buy Guide
BGLC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGLC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CLBR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLBR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BGLC nor CLBR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.